Tokio Marine Asset Management Co. Ltd. Grows Holdings in Solventum Co. (NYSE:SOLV)

Tokio Marine Asset Management Co. Ltd. grew its holdings in shares of Solventum Co. (NYSE:SOLV) by 5.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,227 shares of the company’s stock after buying an additional 261 shares during the quarter. Tokio Marine Asset Management Co. Ltd.’s holdings in Solventum were worth $345,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Worldquant Millennium Advisors LLC lifted its stake in Solventum by 373.6% during the third quarter. Worldquant Millennium Advisors LLC now owns 47,665 shares of the company’s stock worth $3,323,000 after purchasing an additional 37,600 shares during the last quarter. Harbor Capital Advisors Inc. lifted its stake in Solventum by 24.8% during the fourth quarter. Harbor Capital Advisors Inc. now owns 46,965 shares of the company’s stock worth $3,103,000 after purchasing an additional 9,333 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in Solventum by 37.4% during the third quarter. The Manufacturers Life Insurance Company now owns 117,853 shares of the company’s stock worth $8,217,000 after purchasing an additional 32,051 shares during the last quarter. State Street Corp lifted its stake in Solventum by 3.1% during the third quarter. State Street Corp now owns 6,107,550 shares of the company’s stock worth $425,818,000 after purchasing an additional 185,938 shares during the last quarter. Finally, Exchange Traded Concepts LLC lifted its stake in Solventum by 1,593.6% during the fourth quarter. Exchange Traded Concepts LLC now owns 14,650 shares of the company’s stock worth $968,000 after purchasing an additional 13,785 shares during the last quarter.

Analyst Upgrades and Downgrades

SOLV has been the topic of several research analyst reports. Stifel Nicolaus initiated coverage on Solventum in a research note on Tuesday, October 8th. They set a “buy” rating and a $82.00 price objective on the stock. Morgan Stanley raised their price objective on Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a research note on Monday, November 11th. Mizuho began coverage on Solventum in a research report on Wednesday, December 4th. They issued a “neutral” rating and a $70.00 target price on the stock. Finally, Piper Sandler increased their target price on Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a research report on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has given a buy rating to the stock. According to data from MarketBeat.com, Solventum presently has an average rating of “Hold” and an average target price of $68.29.

Solventum Stock Up 1.4 %

Shares of SOLV opened at $74.62 on Wednesday. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. Solventum Co. has a one year low of $47.16 and a one year high of $96.05. The stock’s fifty day moving average is $70.21 and its 200-day moving average is $67.57.

Solventum (NYSE:SOLV) last issued its quarterly earnings results on Thursday, November 7th. The company reported $1.15 EPS for the quarter, missing analysts’ consensus estimates of $1.38 by ($0.23). The firm had revenue of $2.08 billion during the quarter, compared to the consensus estimate of $2.05 billion. Analysts forecast that Solventum Co. will post 6.58 EPS for the current year.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.